Medical Devices

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

Compugen adds strategic powerhouse Dr. Michele Holcomb to its board, a move signaling its ambition to convert AI-driven discoveries into market value.

With over $10M in new funding, Berlin Heals is advancing a novel implant that uses a gentle electrical field to potentially reverse heart failure damage.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A potential first therapy for Charcot-Marie-Tooth disease heads to a major conference, showing promising functional gains despite missing its primary goal.

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

As Caroline Dorsa retires, Biogen elects Dr. Maria Freire as its new chair, a strategic move placing deep scientific expertise at the helm for a critical period.

The health tech firm posts strong revenue and positive EBITDA, but SEC filings and a falling stock price reveal a more complex and challenging road ahead.

The American Academy of Orthopaedic Surgeons awards 14 grants to address a stark diversity crisis in one of medicine's least representative fields.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

A non-invasive device for spinal cord injury gains major international praise, signaling a shift in neurorehabilitation and a path to market.

After a decade-long battle with Stage 4 cancer, one patient's cure spotlights a revolutionary immunotherapy and its potential to change cancer treatment.

Newly independent medical logistics firm GMLx hires its first senior leader, signaling an aggressive expansion strategy in a complex supply chain market.

Insight Molecular Diagnostics secures $26M to expand its transplant rejection test to the heart market, backed by a major shareholder amid market dilution concerns.

SOFIE Biosciences' FAPI-PRO trial begins, testing a novel radiotracer that could revolutionize the detection of one of the deadliest forms of cancer.

Daré Bioscience launches telehealth for DARE to PLAY™, the first evidence-backed topical sildenafil cream designed to address female sexual arousal.